Investor Presentaiton

Profit & Loss - Consolidated Revenue In NT$ million, except for EPS FY 2017 (Unaudited) 3,516 100% FY 2016 (Audited) YOY Cost of Goods Sold (1,966) -56% 4,031 100% (2,225) -55% -13% (note) 12% Gross Profit 1,550 44% 1,806 45% -14% Operating Expense (991) -28% (938) -23% -6% Operating Income 559 16% 868 22% -36% Non-operating Income, Net (84) -2% (58) -1% -45% Income before Tax 475 14% 811 20% -41% Net Income 422 12% 659 16% -36% EPS (NT$) 0.53 0.83 EBITDA 986 28% 1,294 32% -24% * Total outstanding shares were 790.739m units at 12/31/2017. 16 Note: 2016 vs 2017: 5.96% NTD appreciation against USD YoY ScinoPharm

View entire presentation